We are beginning to understand the biological basis of aging and age-related diseases, making the discovery of new therapies actionable for the first time. This is a promising new area in science with the potential for a meaningful impact on human healthspan. The benefits emerging from anti-aging science have enormous potential for the treatment of age-related conditions, such as cardiometabolic and kidney diseases, osteoarthritis, immunosenescence and neurodegeneration. The mechanistic target of rapamycin (mTOR) and cellular senescence are two fields of scientific discovery being pursued as domains for new drug development. Session attendees will hear from the leaders at these companies who are translating findings into new pharmacological interventions that impact the core biological aging mechanisms, which are increasingly recognized as catalysts for a wide range of poorly treated prevalent diseases.